associated with HPV16 and 10% are associated with other high-risk HPV types (Walline et al. 2013) . The HPV16 genome is a 7.9-kb circular genome organized into 6 early region genes and 2 late region genes (Fig. 1) . HPV is dependent on the host cell for replication. The viral proteins manipulate cellular pathways for viral genome replication/amplification and coordinate these processes with the cellular differentiation pathway, timing viral capsid production with the later stages of epithelial differentiation. The HPV oncoproteins E6 and E7 induce host cell replication by blocking the function of key cell cycle regulators, TP53 and RB1. The viral E6 protein binds to cellular TP53 and induces ubiquitinmediated degradation ( Fig. 2A ) (Scheffner et al. 1990 ). HPV E7 protein binds to the RB1 pocket, thereby inhibiting its interaction with the transcription factor E2F, resulting in unscheduled transcription of cell cycle entry genes (Boyer et al. 1996) (Fig. 2B) . The E6 gene can be expressed as full-length or alternatively spliced forms, referred to as E6*I, E6*II, or E6*III. These alternate transcripts are thought to be drivers of oncogenic transformation (Sathish et al. 2004 ). The hrHPV E1 and E2 genes play an essential role in viral replication, and E2 is a transcriptional repressor of E6 and E7. Persistent HPV infection that leads to carcinoma is characterized by high expression of E6 and E7 and frequent loss of E2, leading to unregulated expression of E6 and E7, which promotes genomic instability, oncogenic transformation, and clonal expansion (Wiest et al. 2002) .
Although the incidence of HPVinduced cervical cancer has decreased due to improved screening and early intervention, the rate of HPV-associated head and neck cancers has been increasing (Chaturvedi et al. 2008; Brouwer et al. 2016) . In 2009, there were more incident cases of oropharynx cancer than cervical cancer in the United States (Jemal et al. 2013) . This is in contrast to HPV-negative head and neck cancers, which represent a distinct clinical entity and have been declining in incidence, primarily due to public health efforts to decrease smoking. HPV-positive cancer is more likely to develop in the oropharynx than in the oral cavity, and it is E6 and E7 are the viral oncoproteins of HPV that function to disrupt cell cycle control mechanisms in the host cell, driving cell proliferation and viral replication. The other "early" genes, E1, E2, E4, and E5, encode proteins that have roles in viral replication. E2 is also involved in controlling viral oncogene expression. One function is to serve as a transcriptional repressor of E6 and E7, coordinating the viral life cycle with keratinocyte differentiation. After viral genome amplification in the suprabasal cells, E6 and E7 expression is attenuated and viral capsid production begins. The 2 "late" genes, L1 and L2, encode for structural proteins that constitute the viral capsid necessary for packaging and transmission of the newly replicated virus (Munger et al. 2004 ). The human papillomavirus (HPV) oncoprotein E6 recruits the cellular E3 ubiquitin ligase, E6-associated protein (E6AP) (Talis et al. 1998) , and binds TP53, leading to TP53 polyubiquitination and subsequent degradation by the 26S proteasome. The destruction of TP53 results in failure of cell cycle arrest and apoptosis, contributing to unrestricted host cell growth and proliferation. (B) In normal cells, the cell cycle regulator RB binds the transcription factor E2F, preventing cell cycle progression. When cell growth signaling occurs, expression of cyclin D1 is initiated. Cyclin D1 activates cyclin-dependent kinase (CDK) 4/6, leading to monophosphorylation of RB. CDK2 is then activated by cyclin E and further phosphorylates RB, releasing E2F and initiating transcription of cell cycle entry genes. E2F also activates transcription of p16INK4a (CDKN2A, an inhibitor of cyclindependent kinase 4 and the off signal for RB phosphorylation), shutting off RB phosphorylation. Ubiquitous phosphatase activity dephosphorylates RB, which resequesters E2F and stops cell cycle entry. In the presence of HPV, E7 binds to the pocket of RB, disrupting the interaction with E2F. When E2F is liberated, it leads to continual transcription of S-phase genes, driven by other cell cycle cyclin-CDK complexes. p16INK4a is also inappropriately transcribed and expressed, making it a useful surrogate histological marker of HPV infection. The binding of E7 to RB leads to continuous cell cycle entry, progression, and cellular proliferation.
suggested that this is due to the architecture of tonsillar crypts in the oropharynx, which act as a reservoir for HPV. The palatine and lingual tonsils are the most common sites of origin for HPV-induced oropharyngeal cancer (Paz et al. 1997; Gillison et al. 2000) . Patients with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) have a survival advantage over those with HPV-negative OPSCC regardless of treatment modality (Gillison et al. 2000; Licitra et al. 2006; Fakhry et al. 2008; Worden et al. 2008) . Patients with HPV-positive OPSCC tend to respond better to chemoradiation therapy (Feng et al. 2010) and have enhanced radiosensitivity (Ziemann et al. 2015) . HPV-negative patients generally have a higher mutational burden, particularly mutant TP53, which may contribute to their worse prognosis . However, patients with HPV-positive oral cavity squamous cell carcinoma (OCSCC) do not have the same survival advantage over patients with HPV-negative OCSCC (Fakhry et al. 2017) ; some studies suggest they have a worse prognosis (Duray et al. 2012) . A meta-analysis by Ragin and Taioli (2007) showed no survival difference between HPV-positive and HPV-negative patients with cancer at nonoropharyngeal sites of the head and neck, including oral cavity. The source of the discrepancy in outcome between the oropharynx and oral cavity is not entirely clear, but differences in immune response from site to site may be an important factor (Duray et al. 2014 ).
Integration in Cervical Carcinomas
HPV typically persists in cells as a circular episome but can also linearize and become integrated into the host genome. It has been of great interest to understand the implications of integration and to determine whether it is involved in tumor formation. HPV is commonly found integrated into the host genome in cervical cancer (Klaes et al. 1999; Vinokurova et al. 2008) . Integration of HPV is characteristic of cervical lesion progression but may not be required for tumor formation (Klaes et al. 1999; Wentzensen et al. 2004) . Early studies investigating the role of integration in cervical lesions showed that integration is a stochastic process or favors a preference for common fragile sites, regions of microhomology, highly transcriptionally active regions, or near microRNAs (miRNAs) (Ziegert et al. 2003; Wentzensen et al. 2004; Hu et al. 2015) . There were few reported examples of integration into genes that led to a disruption of gene expression, and in general, integration was not presumed to have any major impact on gene expression. Integration near the cMYC locus on chromosome 8q24 has been shown to lead to overexpression of cMYC; this locus may be a preferential target site for integration of HPV18 (Ferber et al. 2003) . Later studies, however, showed that integration of HPV might represent an additional oncogenic mechanism through direct alteration of cancer-related gene expression. One study showed that most integration events occur in known or predicted genes or near miRNAs, which have major roles in regulation of cellular processes (Schmitz et al. 2012) . A more recent study by Hu et al. (2015) showed that integration events occur in genomic hotspot regions and may function to inactivate or activate genes that favor clonal expansion. Bodelon and colleagues (2016) analyzed over 1,200 integration events in cervical cancers and reported that integration occurred most frequently at 3 loci: 3q28, 8q24.21, and 13q22.1. These regions all are gene rich and contain important tumor suppressors, including TP63, TPRG1, MYC, and KLF5 and KLF12. They also reported that integration into genes occurs more often than expected by chance and may lead to functional alteration of important genes. Integration events in cervical cancer have been better described than in head and neck cancer, but still much is not understood about the role integration plays on the progression from dysplasia to invasive carcinoma.
How Is Integration Detected?
Whether integration of HPV is required for malignant transformation in oral cancers is not clear. The wide variety of techniques used to detect integration events makes it challenging to compare results of different studies. The most commonly used methods to detect integrated HPV sequences are detection of integrated papillomavirus sequences-polymerase chain reaction (DIPS-PCR), amplification of papillomavirus oncogene transcripts (APOT), whole-genome sequencing (WGS), wholeexome sequencing, and RNA-seq. DIPS-PCR and APOT are PCR-based methods used to detect fusions at the DNA and RNA level, respectively. These 2 methods are technically simpler and cheaper options than larger-scale sequencing methods like WGS or RNA-seq but may be unable to detect all integration sites and complicated structural changes within samples. Therefore, WGS and RNA-seq may better reflect the true complexity of viral integration using tiling of paired ends across the genome. Many groups use an E2/E6 gene expression ratio to represent the physical state of HPV, based on the hypothesis that during integration, the E2 gene is disrupted, leading to increased levels of E6. In this method, a ratio is made comparing the expression levels of the E2 and E6 genes as measured by quantitative PCR (qPCR), assuming that a ratio of 1 means HPV is episomal and a ratio of less than 1 means HPV is integrated. This method is not as effective as others because it is based on the assumption that E2 is always disrupted and E6 is always increased during integration, which has been shown to not be true in all cases (Parfenov et al. 2014; Hu et al. 2015; Gao et al. 2017 ).
Where Does HPV Integration Occur in HNSCCs?
Like in cervical cancers, there is no consensus sequence or 1 location where HPV integration is known to target in oral and oropharyngeal cancers. Integration breakpoints have been reported throughout the cellular genome. In HNSCC cell lines, Akagi et al. (2014) reported that HPV insertional breakpoints were found at regions of genomic amplification or deletion and demonstrated an association of insertional breakpoints with structural variation, including chromosomal translocations, deletions/insertions, and rearrangements. Parfenov and colleagues (2014) analyzed the genomic landscape of the 35 HPVpositive HNSCCs in The Cancer Genome Atlas (TCGA), including both OPSCCs and OCSCCs, by WGS and found over 100 integration sites in 25 of the tumors. Integration into a known gene was seen in 54% of the events, and 17% integrated within 20 kb of a gene. Walline et al. (2017) investigated 9 HNSCC cell lines by DIPS-PCR and found integration in all cell lines throughout the cellular genome, 8 of which had integration into cancer-related genes.
What Is the Mechanism of Integration?
The exact mechanism of HPV integration into the host genome is not known. In most models, both the viral and cellular genomes undergo breakage, allowing for fusion between the two. Some groups assert that fusion occurs as a result of cellular repair mechanisms, including nonhomologous end joining and homologous recombination (Senapati et al. 2016 ). However, others have criticized these proposed mechanisms because small numbers of breakpoints are seen even when many copies of HPV are present, which argues against random breakpoints (Akagi et al. 2014) . Akagi et al. (2014) developed a looping model for focal genomic instability to explain the genomic structural variations seen in HNSCC cell lines using a chromosomal mapping technique to determine the DNA structure surrounding integration sites. In this model, both the host and viral genomes are nicked, the viral genome is inserted, and a circular piece of DNA containing both is transiently formed, resulting in rolling circle amplification. This amplification leads to concatemer formation characterized by amplified segments of a genomic sequence flanked by HPV segments. This is consistent with reports from patient tumors with focal copy number elevation at sites of HPV integration (Parfenov et al. 2014; Cancer Genome Atlas Network 2015) .
How Does Integration Promote Oncogenesis in HNSCC?
Integration has been thought to promote oncogenesis through the dysregulation of the oncoproteins E6 and E7, resulting in increased cellular proliferation and genetic instability (Jeon and Lambert 1995) . Dysregulation of E6 and E7 gives the cells a selective growth advantage and allows for oncogenic progression. Multiple events have been described that result in dysregulation of E6/E7, including disruption of E2 or its binding sites, disruption of E1, formation of stable viral-host transcripts, or generation of a viral super-enhancer from repeats of regulatory elements (McBride and Warburton 2017). E2 is responsible for regulation of E6/E7, so disruption of the E2 gene or its binding sites allows for unregulated E6/E7 transcription. When E1 is disrupted, lack of replicative functions can induce DNA damage and growth arrest, promoting focal instability at the site of integration (Sakakibara et al. 2011) . It has been shown that integration can generate hybrid E6/E7 viral-host fusion transcripts, which are often more stable than viral E6/E7 transcripts (Jeon and Lambert 1995) . Dooley et al. (2016) recently showed that a Brd4-dependent super-enhancer, capable of driving expression of viral E6/E7, can be generated from tandem integrated repeats of HPV16 DNA. However, both Parfenov et al. (2014) and Olthof et al. (2014) reported that there are tumors with HPV integration that do not have E2 disruption leading to increased E6/E7. Olthof et al. (2014) reported that there was no significant difference in E2, E6, or E7 levels between integrated versus nonintegrated tumors. This suggests that increased E6/E7 is not always the main driver of oncogenesis.
What Is the Effect of Integration on Cellular Genes?
Integration has traditionally been thought of as promoting oncogenesis through sustained expression of E6 and E7. However, integration has more recently been shown to have effects on cellular gene expression, which may represent an additional oncogenic mechanism in the development of HNSCC (Table) . Parfenov et al. (2014) saw increases in somatic DNA copy number of the integrated region and reported that gene disruption occurs by integration through several key mechanisms: tumor suppressor loss of function, enhanced oncogene expression, and rearrangements that lead to altered gene expression.
Loss of function of a tumor suppressor occurs when HPV integration into a gene results in deletion of gene regions and generates truncated transcripts, as well as host-viral fusion transcripts. Parfenov et al. (2014) reported integration into RAD51, resulting in a 28-fold amplification extrachromosomally, leading to alternate transcripts being generated and likely nonfunctional RAD51 protein. They also reported integration into ETS2, which led to deletion of exons 7 and 8. The overall expression of the gene was unaffected, but transcription of exons 7 and 8 was decreased, likely leading to a truncated protein.
HPV integration upstream of an oncogene can lead to oncogene overexpression via amplification of the nearby downstream region, leading to elevated transcripts. Parfenov et al. (2014) reported viral integration upstream of NR4A2, leading to a 250-fold amplification of the downstream region and subsequent overexpression of NR4A2. NR4A2 is a transcription factor that is overexpressed in a wide variety of human cancers (Safe et al. 2014 ). Parfenov et al. also reported interchromosomal translocation of chromosomes 3 and 13, which caused overexpression of key oncogenes KLF5, TP63, and TPRG1. Walline et al. (2017) characterized integration sites of 8 HPV-positive HNSCC cell lines (7 HPV16 and 1 HPV18) by DIPS-PCR. Integration into cancer-related genes was detected in all of the HPV16 cell lines. The HPV18 cell line, UM-SCC-105, had 2 integration events, but both were intergenic. In UM-SCC-104, viral integration of HPV16 E1 into the tumor suppressor DCC was detected. When the transcripts of the DCC gene were interrogated, no transcripts were generated. This demonstrates an example of viral integration leading to disruption of a tumor suppressor, potentially providing a growth advantage for those cells. In UM-SCC-47, integration into TP63 resulted in the generation of a hybrid viral-host fusion transcript between HPV16 E2 and exon 14 of TP63, which resulted in a truncated ΔNTP63 protein as shown by Western blot. The other cell lines did not exhibit viral-host fusion transcripts, potentially due to integration in frame into introns that were subsequently spliced out. Akagi et al. (2014) investigated whether the rearrangements resulting from integration generated cell-virus fusion transcripts and altered cellular gene expression. In all 10 HNSCC cell lines analyzed and in 1 primary tumor, they found virushost fusion transcript expression, which frequently confirmed the rearrangements described by WGS. They also reported multiple examples of gene disruption at sites of integration. In UD-SCC-2, HPV integration led to deletions and rearrangements of the segment of DIAPH2, which resulted in viralfusion transcripts but no native transcripts or functional protein.
In UM-SCC-47, they reported aberrant TP63 expression due to HPV integration-mediated amplification, leading to viral-host transcripts and a truncated TP63 protein. They saw additional examples of gene disruption, including amplification of the oncogenes FOXE1 and PIM1 in UPCI:SCC090 cells.
However, Olthof et al. (2014) examined patient tumors and saw no significant effect of integration on gene expression, nor were messenger RNA (mRNA) levels of disrupted genes significantly different. Even when HPV was integrated directly into a gene, the mRNA expression levels were not significantly different from a nondisrupted gene elsewhere in the genome. Either there are other expressed gene copies present that allow overall expression levels to be unchanged, or viral integration did not deregulate genes as assessed by their method.
Deregulation of miRNAs in HPV-positive HNSCCs could result from HPV integration near miRNA sites as has been shown in cervical cancer (Schmitz et al. 2012; Hu et al. 2015) and HNSCC cell lines (Wald et al. 2011) . HPV-positive and HPV-negative HNSCCs have distinct miRNA expression patterns, and miRNA subsets were significantly associated with overall survival, disease-free survival, and distant metastasis in HPV-positive HNSCCs (Lajer et al. 2012; Hui et al. 2013) . Hui et al. (2013) reported 128 miRNAs that were differentially expressed between tumor and normal tissue in OPSCCs and speculated that integration of HPV into the genome near these miRNAs contribute to their deregulation. Wald et al. (2011) reported a subset of miRNAs that had altered expression in HPV16-positive HNSCC cell lines compared to both HPV-negative HNSCC cell lines and immortalized normal keratinocytes. The HPV16-positive cell lines used in this study all have been reported to contain integrated HPV, suggesting a possible role of integration on the deregulation of miRNAs.
How Does Integration Affect Viral Gene Expression?
Many studies investigating HPV integration report breakpoints throughout the viral genome, with an increased incidence in E1 (Parfenov et al. 2014) . The effects of integration on viral gene expression are still not entirely known. Akagi et al. (2014) reported that loss of viral segments upon integration or rearrangement contributes to nonuniform coverage of the viral genome when analyzed by RNA-seq. Despite this, viral fragments containing E6 and E7 were retained, and all samples had strong E6/E7 expression. Walline et al. (2017) also reported enhanced E6/E7 expression upon integration, particularly the splice isoform E6*I, and reduced E1/E2 expression in integrationpositive cell lines. E6* transcripts are thought to be drivers of tumor development, so the expression of this isoform at the expense of full-length E6 is significant. Despite many reports of enhanced oncoprotein expression, Parfenov et al. (2014) reported that this does not occur in all integration-positive tumors. Although integration-negative tumors tended to have higher E2/E5 expression levels and lower E6/E7 than integration-positive tumors, this was not always the case. They reported no correlation between the presence of integration within specific HPV genes and their expression level. These results further support the view that HPV plays a larger role in oncogenesis beyond viral oncoprotein expression and subsequent disruption of the p53 and Rb axes.
Can Integration Site Be Clinically Predictive?
After observing integration of HPV16 into cancer-related genes in 7 HNSCC cell lines, 6 established from patients who had progressed, our group investigated integration events in HPV16-positive oropharynx tumors (Walline et al. 2016) . We hypothesized that responsive tumors are driven primarily by viral oncoprotein expression, but recurrent tumors harbor additional carcinogenic events as a result of HPV integration into cancer-related genes. We expected to see integration into cancerrelated genes leading to an alteration in gene expression and potential generation of fusion transcripts in tumors that later recurred but no integration or integration only into cellular intergenic regions in responsive tumors. The integration events in HNSCC tumors from 10 patients were characterized; 5 were responsive after therapy, and 5 recurred after treatment. Our results supported our hypothesis; tumors from responsive patients had integration events into mainly intergenic loci, and tumors from recurrent patients had integration events into cancerrelated genes. Only 1 of the responsive tumors had an integration event into a gene; HPV L1 was found integrated into intron 4 of TP63 on chromosome 3q28. However, when transcript analysis of the region was performed, no fusion transcript was produced, and transcripts across exons 4 and 5, spanning the integration site in intron 4, were produced and were in frame. This suggests that TP63 may not be disrupted by this integration or that at least 1 intact copy of TP63 remains unaltered. All other responsive tumors had only intergenic integration events. In contrast, all 5 of the tumors from recurrent patients had at least 1 integration event into an intron of a cancer-related gene. There were 7 total gene integration events detected in the 5 No transcript generated , and primers spanning the integration site produced a viral-host fusion transcript containing E1 and SMOC1. However, primers from SMOC1 exon 1 to exon 2 and from exon 3 to exon 4 produced no native transcripts of exon junctions spanning the site or of exons downstream of the site. We postulate that the structure includes SMOC1 exon 1 and intron 1 fused to HPV E1-E7-E6, including the viral promoter, with a loss or disruption of SMOC1 downstream exons. Since no normal transcripts were produced, we conclude that both copies of SMOC1 were lost in this tumor. (B) Tumor 0843. A fusion of HPV L2 into SCN2A intron 16 was found at the DNA level. Upon PCR testing of the cDNA using primers spanning SCN2A exon 16_exon 17, a fusion transcript containing SCN2A, HPV L1, and fragments of chromosome 2q32 and 1q32 was produced. No intact SCN2A exon-exon transcripts downstream of the integration site were produced. We postulate that HPV L2 and SCN2A intron 16 are spliced out of the structure shown above, leading to gene disruption that was accompanied by loss of the other copy of SCN2A.
(C) Tumor 2238, integration event 1, NFIA intron 9 fused to HPVL1/L2 and HPVE1. This event failed to yield viral-host fusion transcripts when a primer from exon 9 was paired with an HPV E1 primer. Similarly, PCR testing using primers spanning exons 9 and exon 10 failed to produce a transcript. However, downstream exons 10 to 11 showed in-frame transcripts. It is unclear whether these transcripts come from the affected chromosome or the other copy but suggests that at least 1 copy of the gene is intact, leading us to suspect hemizygous loss of NFIA. (D) Tumor 2238, integration event 2, SEMA6A intron 4 fused to HPVE2. This integration event failed to yield viral-host fusion transcripts by PCR (SEMA6A exon 4 to E2), as well as cellular exon-exon transcripts spanning the integration site (exon 4 to exon 5). In addition, the SEMA6D-HPV E2 integration event also led to lack of cellular exon-exon transcripts downstream of the integration site (exon 5 to exon 6). Because of this, we postulate that gene disruption occurred by homozygous loss of SEMA6D.
tumors, and upon transcript analysis, 4 of the events led to gene disruption (Fig. 3) . The other 3 events did not produce fusion transcripts and retained intact, in-frame cellular gene exon-exon transcripts spanning each respective intronic integration site as well as exon-exon transcripts downstream of the integration site. In tumor 2049 from a recurrent patient, viral integration into SMOC1 led to generation of a SMOC1-HPV E1 fusion transcript. The result of this fusion transcript was inactivation of the gene, demonstrated by the absence of intact cellular exon-exon transcripts surrounding the integration site (Fig. 3A) . Tumor 0843 had integration into SCN2A; transcript analysis revealed a complex rearrangement that produced a fusion transcript containing SCN2A, HPV L1, and fragments of chromosomes 2q34 and 1q32. This integration event failed to yield intact SCN2A exon-exon transcripts downstream of the integration site, suggesting gene disruption (Fig. 3B) . A third tumor, 2238, had 2 integration events that each resulted in gene disruption. In this tumor, HPV L1 was integrated into NF1A and E2 integrated into SEMA6D. Neither of these integration events produced fusion transcripts, but disruption of both genes was evident from the lack of cellular exon-exon transcripts spanning the integration sites. This demonstrates that generation of viral/cellular fusion transcripts is not required for cellular gene disruption to occur (Fig. 3C,  D) . All of the tumors, including those from responsive patients, displayed strong E6/E7 gene expression; E6*I was the highest expressed viral gene in 8 of the 10 tumors (Walline et al. 2016) . Taken together, these results suggest that there are multiple mechanisms leading to integration-mediated cellular gene disruption and that viral integration events can alter gene expression in the host cell. Furthermore, the consequence of these alterations in cellular gene expression may mediate additional carcinogenic mechanisms, leading to a more aggressive tumor phenotype (Fig. 4) . This study, although small, highlights the potential for site of HPV integration to explain clinical outcomes and warrants further investigation. Our model predicts that tumors containing episomal HPV or HPV integrated in intergenic regions are primarily driven by E6/E7 oncogene expression, which are responsive to current therapies. However, tumors with HPV integration into cancer-related genes (or tumors that have integration events that alter expression of microRNAs [Wald et al. 2011] ) will be also driven by altered cellular gene expression. These changes in gene expression can have further oncogenic effects, and therefore the tumor will be more aggressive and nonresponsive to therapy. These tumors are still driven by E6/E7 proteins, due to E1/E2 disruption, unregulated expression of E6/E7, and expression of E6* alternate transcripts linked to increased E7 protein expression. In addition, these tumors often have loss of disrupted genes or overexpressed fusion transcripts that contribute to oncogenesis by mechanisms that are still poorly understood. Figure 5 . Human papillomavirus (HPV) integration into the host genome: effects and potential outcomes. Integration events have been reported to occur as a result of a stochastic process, inserting into readily available regions of the genome or via directed integration into fragile sites, highly transcriptionally active regions with open chromatin, regions of microhomology between HPV and human sequence, or near microRNAs (miRNAs). Integration has been reported to cause a variety of effects on both the HPV and cellular genomes. This includes E1/E2 disruption, expression of alternate E6 transcripts, or creation of viral super-enhancers that drive oncoprotein transcription. Integration can lead to chromosome instability, gene disruption, or regional amplifications within the cellular genome. These effects serve as possible alternate mechanisms increasing HPV-mediated carcinogenesis and largely depend on site of integration, either within an intergenic region or near/within genes. The integration event could have no effect on cellular gene expression if it occurs in an intergenic, nonregulatory region of the genome, although there are reports of integration affecting miRNA expression, which can then alter expression of other genes. Other integration events can lead to E6/E7 viral oncogene overexpression, expression of viral-host fusion transcripts, or gene disruption, including tumor suppressor loss of function and cellular oncogene overexpression.
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Conclusion
There is evidence that HPV integration is implicated in oral/ oropharyngeal cancer oncogenesis, but its exact role remains largely unknown. A variety of mechanisms of integration and their effects on both the viral and cellular genome, as well as likely outcomes, are summarized in Figure 5 . Integration of HPV into the host genome may lead to increased expression of viral oncoproteins, and recent data suggest that viral integration contributes to alterations in host cell gene expression and generation of viral-host fusion transcripts. It is unclear whether integration is required for oncogenesis or if it is consistently associated with a more aggressive, treatment-resistant phenotype. Our work has shown that tumors from patients with recurrent disease are more likely to exhibit integration into cancer-related cellular genes than those from patients who respond to treatment, which contain integration events primarily at intergenic sites. Further investigation of integrationmediated alteration of cellular gene expression, production of viral-host fusion transcripts, and the subsequent effects that contribute to oncogenesis and tumor progression is needed, as are correlative studies on the outcome and survival of patients based on HPV integration status and site. This will establish the feasibility of developing viral integration evaluation as a clinically relevant predictive or prognostic indicator.
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